MLAB vs RDVT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MLAB exhibits a stable financial health profile with a Piotroski F-Score of 6/9, but it is fundamentally disconnected from its valuation. The stock trades at a massive premium to its Graham Number ($22.23) and Intrinsic Value ($4.55), with a trailing P/E of 150.54. While the forward P/E of 18.15 suggests an expected earnings recovery, the current dividend payout ratio of 98.46% is unsustainable. Long-term price performance is severely negative, indicating a persistent lack of value creation over a 5-year horizon.
RDVT presents a dichotomy between exceptional balance sheet health and concerning internal sentiment. While the Piotroski F-Score of 4/9 indicates stability and the company maintains a near-zero debt profile with massive liquidity, the stock is trading at a significant premium to its Graham Number ($12.08) and Intrinsic Value ($26.85). Explosive YoY earnings growth is offset by a bearish technical trend and a highly alarming pattern of C-suite insider selling. Consequently, the strong analyst 'buy' ratings are currently contradicted by the actions of the company's own executives.
Compare Another Pair
Related Comparisons
MLAB vs RDVT: Head-to-Head Comparison
This page compares Mesa Laboratories, Inc. (MLAB) and Red Violet, Inc. (RDVT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.